A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

PHASE3CompletedINTERVENTIONAL
Enrollment

626

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
COPD
Interventions
DRUG

Roflumilast

Roflumilast tablets

DRUG

Placebo

Placebo tablets

DRUG

Salbutamol

Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.

Trial Locations (15)

Unknown

Beijing

Changsha

Chengdu

Chongqing

Fuzhou

Guangzhou

Hangzhou

Nanjing

Nanning

Qingdao

Shanghai

Shenyang

Shijiazhuang

Hong Kong

Singapore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY